Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
While GHK-Cu represents an area of ongoing scientific research, it should not be viewed as a replacement for clinically validated treatments
Yes (strong) FDA status FDA-approved (T2D and obesity) Compound NAD+ (intravenous or subcutaneous) Mechanism Direct NAD+ supplementation Route IV infusion or subcutaneous Acts on appetite
Athiras lead clinical candidate, fosgonimeton (formerly ATH-1017 / NDX-1017), is a structurally distinct phosphate prodrug of Dihexa not Dihexa itself
NICE guidance on weight management emphasises that medications like Mounjaro should be used within multidisciplinary weight management services that provide dietary, physical activity and behavioural support
Practical tips from experienced researchers Beyond the standard procedures, seasoned researchers have developed practical habits that make the entire reconstitution and dosing process smoother
DSIP is a compounded prescription therapy not intended to treat, cure, or prevent any disease
US$ 23.88
US$ 24.35
US$ 24.59
US$ 25.13
US$ 28.57
